In Phase C, contributors will get ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Participants will acquire treatment right up until sickness progression or maybe the contributors are unable to tolerate the study drugs. 88 These preclinical studies provide paradigms for future clinical trials in https://clinicaltrialrecruitmentf70246.dgbloggers.com/32451272/the-fact-about-new-advancements-in-brd4-inhibition-therapy-abbv-744-that-no-one-is-suggesting